Background The efficacy of low-dose lansoprazole is not established for preventing recurrent gastric or duodenal ulcers in those receiving long-term low-dose aspirin (LDA) for cardiovascular and cerebrovascular protection. or duodenal ulcer recurrences, i.e., the principal endpoint, by the end of the analysis was 6/226 (2.7%) within the lansoprazole group and 53/234 (22.6%) within the gefarnate… Continue reading Background The efficacy of low-dose lansoprazole is not established for preventing